Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.

and colleagues conducted a retrospective cohort study to compare the risks for hematologic cancers in patients with T2D treated with a GLP-1 RA vs metformin and insulin. The study included ...

GLP-1 RAs were associated with significant reductions in body weight, BMI, and waist circumference among pediatric patients with obesity.

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP ... needed to further assess and allow comparison of several GLP-1RA agents' impact on steady ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

Annual prevalence of GLP-1 RA use among US adults without diabetes increased from 0.1% in 2018-2021 to 0.4% in 2022, with an estimated 854,728 adults without diabetes taking these medications.

Findings for matched groups of patients with obesity and diabetes taking first-generation GLP-1 RA or undergoing bariatric ... medical records data to compare the incidence of ORC in adults ...